[go: up one dir, main page]

PA8810701A1 - DERIVATIVES OF 19-NOR-STEROID THAT HAS A GROUP 15A, 16A-METHYLENE AND A RING OF 17.17-SATURATED ESPIROLACTONE, ITS USE AND DRUGS THAT UNDERSTAND THEM - Google Patents

DERIVATIVES OF 19-NOR-STEROID THAT HAS A GROUP 15A, 16A-METHYLENE AND A RING OF 17.17-SATURATED ESPIROLACTONE, ITS USE AND DRUGS THAT UNDERSTAND THEM

Info

Publication number
PA8810701A1
PA8810701A1 PA20088810701A PA8810701A PA8810701A1 PA 8810701 A1 PA8810701 A1 PA 8810701A1 PA 20088810701 A PA20088810701 A PA 20088810701A PA 8810701 A PA8810701 A PA 8810701A PA 8810701 A1 PA8810701 A1 PA 8810701A1
Authority
PA
Panama
Prior art keywords
hydrogen
group
derivatives
understand
methylene
Prior art date
Application number
PA20088810701A
Other languages
Spanish (es)
Inventor
Ulrich Klar
Joachim Kuhnke
Rolf Bohlmann
Jan Huebner
Sven Ring
Thomas Frenzel
Frederik Menges
Steffen Borden
Katja Prelle
Hans Peter Muhn
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40548690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8810701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PA8810701A1 publication Critical patent/PA8810701A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LOS DERIVADOS DE y-LACTONA DEL ÁCIDO 15ALFA,16ALFA-METILEN-17-HIDROXI-19-NOR-17-PREGNA-4-en-3-ona-21-CARBOXÍLICO DE LA PRESENTE INVENCIÓN POSEEN EFECTIVIDAD GESTAGÉNICA.TIENEN LA FÓRMULA QUÍMICA GENERAL I,EN LA CUAL Z SE SELECCIONA DEL GRUPO QUE COMPRENDE UN ÁTOMO DE OXÍGENO,DOS ÁTOMOS DE HIDRÓGENO,NOR Y NNHSO2R,DONDE R ES HIDRÓGENO,ALQUILO-C1-C10,ARILO O ARALQUILO-C7-C20,R4 ES HIDRÓGENO O HALÓGENO;ADEMÁS,R6A,R6B FORMAN JUNTOS METILENO O 1,2-ETANDIILO O R6A ES HIDRÓGENO Y R6B SE SELECCIONA DEL GRUPO QUE COMPRENDE HIDRÓGENO,ALQUILO-C1-C10,ALQUENILO-C2-C10 oALQUINILO-C2-C10,Y R7 SE SELECCIONA DEL GRUPO QUE COMPRENDE HIDRÓGENO,ALQUILO-C1-C10,CICLOALQUILO-C3-C6,ALQUENILO-C2-C10 o ALQUINILO-C2-C10,o:R6A ES HIDRÓGENO Y R6B Y R7JUNTOS FORMAN UN ENLACE,UN OXÍGENO O METILENO,R18 REPRESENTA HIDRÓGENO O ALQUILO-C1-C3 Y COMPRENDEN ADEMÁS SUS SOLVATOS,HIDRATOS,ESTEREOISÓMEROS Y SALES.THE DERIVATIVES OF Y-LACTONA OF ACID 15ALFA, 16ALFA-METHYLEN-17-HYDROXI-19-NOR-17-PREGNA-4-en-3-one-21-CARBOXYLIC OF THE PRESENT INVENTION HAVE GESTAGENIC EFFECTIVENESS. HAVE THE GENERAL CHEMICAL FORMULA I, IN WHICH Z IS SELECTED FROM THE GROUP THAT INCLUDES AN OXYGEN ATOM, TWO ATOMS OF HYDROGEN, NOR AND NNHSO2R, WHERE R IS HYDROGEN, ALQUILO-C1-C10, ARILO OR ARALQUILO-C7O CENO H20 ; IN ADDITION, R6A, R6B FORM METHYLENE OR 1,2-ETANDYLL OR R6A IS HYDROGEN AND R6B IS SELECTED FROM THE GROUP THAT INCLUDES HYDROGEN, RENT-C1-C10, ALQUENILO-C2-C10 or ALQUINILO-C2-C7-C7 SELECTION OF THE GROUP THAT INCLUDES HYDROGEN, ALQUILO-C1-C10, CICLOALQUILO-C3-C6, ALQUENILO-C2-C10 or ALQUINILO-C2-C10, or: R6A IS HYDROGEN AND R6B AND R7 JOINTS MAKE ME A LINK, ONE OR REPRESENT HYDROGEN OR RENT-C1-C3 AND ALSO UNDERSTAND THEIR SOLVATOS, HYDRATS, STEREOISOMERS AND SALTS.

PA20088810701A 2007-12-29 2008-12-24 DERIVATIVES OF 19-NOR-STEROID THAT HAS A GROUP 15A, 16A-METHYLENE AND A RING OF 17.17-SATURATED ESPIROLACTONE, ITS USE AND DRUGS THAT UNDERSTAND THEM PA8810701A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007063495A DE102007063495A1 (en) 2007-12-29 2007-12-29 19-nor-steroid derivatives having a 15α, 16α-methylene group and a saturated 17,17-spirolactone ring, their use and medicaments containing these derivatives

Publications (1)

Publication Number Publication Date
PA8810701A1 true PA8810701A1 (en) 2009-12-16

Family

ID=40548690

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088810701A PA8810701A1 (en) 2007-12-29 2008-12-24 DERIVATIVES OF 19-NOR-STEROID THAT HAS A GROUP 15A, 16A-METHYLENE AND A RING OF 17.17-SATURATED ESPIROLACTONE, ITS USE AND DRUGS THAT UNDERSTAND THEM

Country Status (25)

Country Link
US (2) US20100311702A1 (en)
EP (1) EP2238149B1 (en)
JP (1) JP5600071B2 (en)
KR (1) KR20100102136A (en)
CN (1) CN101910192B (en)
AR (1) AR069962A1 (en)
AU (1) AU2008342916A1 (en)
BR (1) BRPI0821666A2 (en)
CA (1) CA2710495C (en)
CL (1) CL2008003919A1 (en)
CO (1) CO6290675A2 (en)
DE (1) DE102007063495A1 (en)
DO (1) DOP2010000199A (en)
EA (1) EA201000982A1 (en)
EC (1) ECSP10010315A (en)
ES (1) ES2539121T3 (en)
IL (1) IL206019A0 (en)
NZ (1) NZ586453A (en)
PA (1) PA8810701A1 (en)
PE (1) PE20091336A1 (en)
TW (1) TW200940074A (en)
UA (1) UA98834C2 (en)
UY (1) UY31580A1 (en)
WO (1) WO2009083272A2 (en)
ZA (1) ZA201005395B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8334375B2 (en) * 2009-04-10 2012-12-18 Evestra, Inc. Methods for the preparation of drospirenone
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
TW201350122A (en) * 2012-04-23 2013-12-16 Bayer Pharma AG Intrauterine use of 18-methyl-15 β , 16 β -methylene-19-nor-20-spirox-4-en-3-ones, intrauterine systems comprising 18-methyl-15 β , 16 β -methylene-19-nor-20-spirox-4-en-3-ones, and use thereof in contraception and gynaecological treatmen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (en) 1962-10-12 1964-12-17 Schering Ag Process for the production of alpha, beta-methylene ketones of the steroid series
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
US4188951A (en) * 1972-08-17 1980-02-19 Alza Corporation Intrauterine system embracing selected copolymeric membranes for administering beneficial agent
NL7701384A (en) 1977-02-10 1978-08-14 Akzo Nv PROCESS FOR PREPARING NEW STEROIDS FROM THE OESTRAINE SERIES.
DE2922500A1 (en) 1979-05-31 1980-12-04 Schering Ag 6 BETA. 7 BETA
DE3402329A1 (en) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ETHYLENE-15,16-METHYLENE-3-OXO-17 (ALPHA) -PREGN-4-EN-21,17-CARBOLACTONE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
DE19651000A1 (en) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
DE102004063864A1 (en) * 2004-12-30 2006-07-13 Schering Ag 18-methyl-19-nor-17-pregn-4-en21,17-carbolactones, as well as pharmaceutical compositions containing them
EP2265629B1 (en) * 2008-03-05 2015-06-24 Evestra, Inc. Bismethylene-17 carbolactones and related uses

Also Published As

Publication number Publication date
HK1151532A1 (en) 2012-02-03
NZ586453A (en) 2012-05-25
KR20100102136A (en) 2010-09-20
JP5600071B2 (en) 2014-10-01
WO2009083272A3 (en) 2009-08-27
ECSP10010315A (en) 2010-08-31
CL2008003919A1 (en) 2010-05-07
CO6290675A2 (en) 2011-06-20
PE20091336A1 (en) 2009-10-04
UA98834C2 (en) 2012-06-25
ES2539121T3 (en) 2015-06-26
EA201000982A1 (en) 2011-02-28
DE102007063495A1 (en) 2009-09-17
IL206019A0 (en) 2010-11-30
EP2238149B1 (en) 2015-03-18
ZA201005395B (en) 2012-01-25
US8987239B2 (en) 2015-03-24
AR069962A1 (en) 2010-03-03
JP2011507928A (en) 2011-03-10
CA2710495A1 (en) 2009-07-09
AU2008342916A1 (en) 2009-07-09
TW200940074A (en) 2009-10-01
US20130123219A1 (en) 2013-05-16
UY31580A1 (en) 2009-08-03
CN101910192A (en) 2010-12-08
CA2710495C (en) 2015-04-28
BRPI0821666A2 (en) 2015-06-16
CN101910192B (en) 2013-07-31
EP2238149A2 (en) 2010-10-13
US20100311702A1 (en) 2010-12-09
WO2009083272A2 (en) 2009-07-09
DOP2010000199A (en) 2010-10-15

Similar Documents

Publication Publication Date Title
PA8784201A1 (en) DERIVED FROM 17B-CIANO-18A-HOMO-19-NOR-ANDROST-4-ENO, ITS USE AND MEDICATION CONTAINING IT
UY31712A1 (en) NEW DERIVATIVES OF DIOSMETINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ECSP14013245A (en) NEW DIHYDROQUINOLINE-2-ONA DERIVATIVES
CL2017000804A1 (en) Spirodiamine derivatives as aldosterone synthase inhibitors
UY30498A1 (en) NEW CLASS OF BENZIMIDAZOLILO COMPOUNDS, ITS SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
CR11251A (en) CYCLE DEPSIPEPTIDES AND USES OF THE SAME
BRPI0718966B8 (en) compound, pharmaceutical composition, plk1 inhibitor and antitumor agent
BR112016001979A2 (en) tetrazolinone compound and its use
CR8889A (en) DERIVATIVES OF N- (1H-INDOLIL) - 1H-INDOL-2- CARBOXAMIDS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
NI201000134A (en) NEW DIHYDROINDOLONE DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
BR112014031741A2 (en) amide compound and its use for pest control
AR088034A1 (en) COMPOUND OF USEFUL CYCLIC AMINE AS A PESTICIDE
PA8784401A1 (en) DERIVED FROM 17B-CIANO-19-NOR-ANDROST-4-ENO, ITS USE AND MEDICATION THAT CONTAINS IT
PA8810701A1 (en) DERIVATIVES OF 19-NOR-STEROID THAT HAS A GROUP 15A, 16A-METHYLENE AND A RING OF 17.17-SATURATED ESPIROLACTONE, ITS USE AND DRUGS THAT UNDERSTAND THEM
AR077429A1 (en) HYDROXIASENAPINA COMPOUNDS ITS DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE SAME
CU20100137A7 (en) DERIVATIVES OF 19-NOR-STEROID THAT HAS A GROUP 15, 16-METHYLENE AND A RING OF 17, 17-SATURATED ESPIROLACTONE, ITS USE AND MEDICINES THAT UNDERSTAND
UY31581A1 (en) DERIVATIVE 15, 16-METHYLEN-17- (1 '- PROPENIL) -17-3' -OXIDOESTRA-4-EN-3-ONA, ITS USE AND MEDICINAL CONTAINING IT
CU20130037A7 (en) NEW DIHYDROBENZOXATIAZEPIN DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CU20120041A7 (en) NEW DIHIDRO-OXAZOLOBENZODIAZEPINONAS DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PA8809901A1 (en) DERIVED FROM Y-LACTONE OF STEROID ACID 15, 16-METHYLENE-17-HYDROXY-19-NOR-21-CARBOXYL, ITS USE AND MEDICINAL PRODUCT CONTAINING IT
CO2020010970A2 (en) Gemcitabine monophosphate small molecule drug conjugates
PA8809701A1 (en) DERIVED FROM Y-LACTONA OF THE STEROID OF THE ´CID 17-HIDROXI-19-NOR-21-CARBOXYL, ITS USE AND THE MEDICINAL PRODUCT CONTAINING IT
DOP2010000201A (en) DERIVED FROM 17- (1 '- PROPENIL) -17-3'-OXIDOESTRA-4-EN-3-ONA, ITS USE AND DRUGS CONTAINING IT
TH104955A (en) 19-nor-steroid derivatives with group 15 (alpha), 16 (alpha)-methylene and saturated 17,17-spirolactone rings. These and pharmaceutical products containing these derivatives.
CU20100139A7 (en) Y-LACTONE DERIVATIVES OF ACID STEROID 15,16-METHYLEN-17-HYDROXY-19-NOR-21-CARBOXYLIC, ITS USE AND MEDICATIONS CONTAINING SUCH DERIVATIVE